Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

What are the company's profit margins for the quarter, and have there been any notable changes in cost structure? Did the company provide guidance or outlook for future quarters or the full‑year 2025? Are there any significant corporate developments (e.g., partnerships, acquisitions, regulatory approvals) that could affect future performance? How does Journey Medical's Q2 performance compare to its direct competitors in the medical device/healthcare sector? What is the cash‑flow situation and balance‑sheet strength after the reported results? Is there any insider trading activity or notable changes in institutional ownership following the release? What potential catalysts (e.g., FDA approvals, product launches) could drive the stock price in the near term? What was the year‑over‑year growth rate for Q2 2025 revenue compared to Q2 2024? Did Journey Medical report any net income or loss for the quarter, and what was the earnings per share? How does the $15 million revenue figure compare to the company's historical revenue trends and analyst expectations?